Indeed, KL-6 serial measurements could be valuable to assess disease progression over time in ILDs, including IPF, while baseline serum levels may predict the risk of AE-IPF [37,38]. This evidence concerns the gene MUC1 and idiopathic pulmonary fibrosis.